China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population
Safety and Effectiveness of Edwards Lifesciences SAPIEN XT Transcatheter Heart Valve in the Chinese Population
Sponsor: Edwards Lifesciences
A NA clinical study on Aortic Regurgitation and Aortic Stenosis, this trial is completed. The trial is conducted by Edwards Lifesciences and has accumulated 12 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Oct 2023 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Sep 2022 — Oct 2023 [monthly]
Active Not Recruiting NA
-
Oct 2021 — Sep 2022 [monthly]
Active Not Recruiting NA
▶ Show 7 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting NA
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Aug 2020 — Oct 2020 [monthly]
Active Not Recruiting NA
-
May 2020 — Aug 2020 [monthly]
Active Not Recruiting NA
-
Feb 2020 — May 2020 [monthly]
Active Not Recruiting NA
-
Mar 2019 — Feb 2020 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Nov 2017 — Mar 2019 [monthly]
Recruiting NA
First recorded
Sep 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Edwards Lifesciences
For direct contact, visit the study record on ClinicalTrials.gov .